Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted Psychotherapy + MBSR for COVID-19 Related Burnout
NCT05557643Phase 1Completed
- Sponsor
- University of Utah
- Start
- Jan 2023
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of psilocybin in major depressive disorder (MDD) and burnout syndrome (2 arms), sponsored by University of Utah. Primary endpoint: Quick Inventory of Depressive Symptomatology - Self Report at 6 months. Started Jan 2023; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)burnout syndrome
Beyond the preview
Go deeper on NCT05557643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557643.